Canton Strategic Holdings (CNTN) Income towards Parent Company (2021 - 2026)
Canton Strategic Holdings posted quarterly Income towards Parent Company of -$47.3 million for Q1 2026, down 1762.66% year-on-year from $2.8 million in Q1 2025, and down 1939.47% on a QoQ basis from -$2.3 million in Q4 2025.
Canton Strategic Holdings (CNTN) has 6 years of Income towards Parent Company data on file, last reported at -$47.3 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 1762.66% year-over-year to -$47.3 million; the trailing twelve-month figure through Mar 2026 stood at -$53.6 million (down 330.72% YoY), and the FY2025 full-year result was -$35.9 million, down 194.45% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$47.3 million, down from -$2.3 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$1.6 million in Q2 2022 and bottomed at -$47.3 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$2.3 million (2024), against an average of -$5.1 million.
- The widest annual swing landed in 2025, when Income towards Parent Company soared 44.63%; it then plunged 1762.66% in 2026.
- A 5-year view of Income towards Parent Company shows it stood at -$1.8 million in 2022, then slumped by 40.74% to -$2.5 million in 2023, then sank by 53.08% to -$3.8 million in 2024, then surged by 38.7% to -$2.3 million in 2025, then tumbled by 1939.47% to -$47.3 million in 2026.
- The last three Income towards Parent Company figures came in at -$47.3 million (Q1 2026), -$2.3 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Canton Strategic Holdings | 643.89 Mn | 602.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -47.34 Mn |
| Dec 31, 2025 | -2.32 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.79 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -1.76 Mn |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,593.00 |
| Sep 30, 2021 | -777,113.00 |
| Jun 30, 2021 | -1.29 Mn |
| Mar 31, 2021 | -1.62 Mn |